Replimune Group (NASDAQ:REPL) Sees Large Volume Increase – Time to Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) saw strong trading volume on Wednesday . 2,589,778 shares traded hands during trading, an increase of 73% from the previous session’s volume of 1,494,138 shares.The stock last traded at $6.9770 and had previously closed at $7.01.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and increased their price target for the company from $4.00 to $18.00 in a research report on Monday, October 20th. Leerink Partnrs upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research report on Monday, October 20th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $3.00 to $13.00 in a research report on Monday, October 20th. Finally, Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.75.

Replimune Group Price Performance

The firm has a market cap of $551.22 million, a P/E ratio of -2.03 and a beta of 0.72. The business’s fifty day simple moving average is $9.27 and its 200-day simple moving average is $7.49. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). As a group, analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Activity

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $47,392.80. Following the sale, the insider directly owned 123,088 shares of the company’s stock, valued at $1,120,100.80. This represents a 4.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 25,625 shares of company stock valued at $257,607. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its holdings in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Replimune Group by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after purchasing an additional 6,873 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Replimune Group in the 2nd quarter worth about $69,000. GSA Capital Partners LLP purchased a new position in shares of Replimune Group during the 3rd quarter valued at about $81,000. Finally, Griffin Asset Management Inc. purchased a new position in shares of Replimune Group during the 3rd quarter valued at about $82,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.